Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Year in Review
  • Published:

Multiple sclerosis in 2016

Immune-directed therapies in MS — efficacy and limitations

Nature Reviews Neurology volume 13, pages 72–74 (2017)Cite this article

Subjects

In 2016, new highly active treatment options for relapsing–remitting multiple sclerosis (MS) emerged. At the same time, large clinical trials in progressive MS highlighted the limitations of immune-directed therapies, and called for new strategies to treat disease progression in MS.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Alping, P. et al. Rituximab versus fingolimod after natalizumab in multiple sclerosis patients. Ann. Neurol. 79, 950–958 (2016).

    Article  CAS  Google Scholar 

  2. Hauser, S. et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N. Engl. J. Med. http://dx.doi.org/10.1056/NEJMoa1601277 (2016).

  3. Atkins, H. L. et al. Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial. Lancet 388, 576–585 (2016).

    Article  Google Scholar 

  4. Lublin, F. et al. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 387, 1075–1084 (2016).

    Article  CAS  Google Scholar 

  5. Montalban, X. et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N. Engl. J. Med. http://dx.doi.org/10.1056/NEJMoa1606468 (2016).

  6. Steiner, D. et al. Natalizumab versus placebo in patients with secondary progressive multiple sclerosis (SPMS): results from ASCEND, a multicenter, double-blind, placebo-controlled, randomized phase 3 clinical trial. BioGenConferences http://biogenconferences.com/AAN2016/Tysabri/TYS_Steiner_ASCEND_SPMS_Primary_data.pdf (2016).

  7. Jürgens, T. et al. Reconstruction of single cortical projection neurons reveals primary spine loss in multiple sclerosis. Brain 139, 39–46 (2016).

    Article  Google Scholar 

  8. Cortese, M. et al. Preclinical disease activity in multiple sclerosis: a prospective study of cognitive performance prior to first symptom. Ann. Neurol. 80, 616–624 (2016).

    Article  Google Scholar 

  9. Kantarci, O. H. et al. Primary progressive multiple sclerosis evolving from radiologically isolated syndrome. Ann. Neurol. 79, 288–294 (2016).

    Article  Google Scholar 

  10. Confavreux, C. & Vukusic, S. Natural history of multiple sclerosis: a unifying concept. Brain 129, 606–616 (2006).

    Article  Google Scholar 

Download references

Acknowledgements

B.H. and M.M. were supported by the German Competence Network Multiple Sclerosis' (German Ministry for Research and Education). B.H. was supported by the Transregional Collaborative Research Center (CRC) SFB TR-128, and M.M. by the Hertie Foundation.

Author information

Authors and Affiliations

  1. Bernhard Hemmer is at the Department of Neurology, Klinikum rechts der Isar, Technical University of Munich, Ismaninger Strasse 22, 81675 Munich, Germany and affiliated with the Cluster for Systems Neurology (SyNergy).,

    Bernhard Hemmer

  2. Mark Mühlau is at the Department of Neurology, Klinikum rechts der Isar, Technical University of Munich, Ismaninger Strasse 22, 81675 Munich, Germany and affiliated with the TUM-Neuroimaging Center (TUM-NIC).,

    Mark Mühlau

Authors
  1. Bernhard Hemmer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mark Mühlau
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bernhard Hemmer.

Ethics declarations

Competing interests

B.H. has served on scientific advisory boards for Novartis, Bayer Schering, F. Hoffmann-La Roche, AllergyCare and Genentech. He has received honoraria for lectures from Teva Pharmaceutical Industries, Biogen Idec, Medimmune, Merck Serono and F. Hoffmann-La Roche, and has received research support from Chugai Pharmaceuticals and F. Hoffmann-La Roche. He has filed two patents, one for the detection of antibodies and T cells against KIR4.1 in a subpopulation of multiple sclerosis patients, and one for genetic determinants of neutralizing antibodies to IFNβ. M.M. has received research support from Merck Serono and Novartis.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hemmer, B., Mühlau, M. Immune-directed therapies in MS — efficacy and limitations. Nat Rev Neurol 13, 72–74 (2017). https://doi.org/10.1038/nrneurol.2017.2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneurol.2017.2

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing